Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00259610 · ClinicalTrials.gov registry record · Phase 4
Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 755
- Enrollment target
NCT00259610 is a Phase 4 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 755 participants.
The verdict
NCT00259610, a Phase 4 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 755 participants
- Enrollment target
Study Summary
The purpose of this study is to 1)to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanercept or reserve this treatment for patients who do not appropriately respond to methotrexate alone and 2) to determine which combination of methotrexate therapy is better
Interventions
- DRUG methotrexate
- DRUG hydroxychloroquine
- DRUG etanercept
- DRUG sulfasalazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 755 participants |
| Start Date | 2004-05 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00259610
The ClinicalTrials.gov registry entry for NCT00259610 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 755 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which methotrexate is the first listed.
NCT00259610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00259610 about?
NCT00259610 is a clinical study titled "Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)". The purpose of this study is to 1)to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanercept or reserve this treatment for patients who do not appropriately respond to methotrexate alone an...
What is the current status of trial NCT00259610?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 755 participants. The study started on 2004-05. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00259610?
The interventions under investigation include: methotrexate (DRUG), hydroxychloroquine (DRUG), etanercept (DRUG), sulfasalazine (DRUG).
Who is sponsoring clinical trial NCT00259610?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.